PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis

Publication: EMJ Oncol. 2024;12[1]:138-147. Authors: C. Jackisch, D. Pronin, Christa Dreezen, T. Dimpfl, R. Büttner, G. Kunz, C. Langwieder, M. Rees, K. Lerchl Title: MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis Abstract INTRODUCTION: Gene expression assays, Read More

Identification of Racial Disparities (ESMO 2024)

Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Background: Black women in the Read More